Highlights
- EPS (TTM)
- -$0.93
- Total Revenue (TTM)
- $4.69M
- Gross Profit (TTM)
- -$7.70M
- EBITDA (TTM)
- -$10.12M
- Year Range
- $0.81 - $4.07
- ROA (TTM)
- -0.00%
- ROE (TTM)
- -0.00%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Marker Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Marker Therapeutics Inc (MRKR) has returned -12.75% so far this year and 5.69% over the past 12 months. Over the last ten years, MRKR has returned -34.25% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Marker Therapeutics Inc
- 1D
- 4.84%
- 1M
- -12.16%
- YTD
- -12.75%
- 6M
- 45.64%
- 1Y
- 5.69%
- 3Y*
- 22.34%
- 5Y*
- -43.15%
- 10Y*
- -34.25%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 25, 2014, MRKR's average daily return is +0.02%, while the average monthly return is +0.17%. At this rate, your investment would double in approximately 34.0 years.
Historically, 36% of months were positive and 64% were negative. The best month was Jun 2015 with a return of +190.0%, while the worst month was Mar 2023 at -67.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, MRKR closed higher 44% of trading days. The best single day was Aug 5, 2022 with a return of +63.6%, while the worst single day was Jan 12, 2015 at -40.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.38% | -7.50% | -12.16% | -12.75% | |||||||||
| 2025 | -40.84% | -16.85% | -19.61% | -3.25% | 31.09% | -1.92% | -8.50% | -33.88% | -3.58% | 10.65% | 25.54% | 20.16% | -52.09% |
| 2024 | -15.64% | -21.77% | 18.46% | -5.81% | -4.44% | 40.31% | -9.94% | -26.18% | -21.88% | 43.62% | -13.58% | -11.14% | -43.45% |
| 2023 | 5.30% | -22.50% | -67.28% | 18.51% | 111.55% | 74.16% | 62.90% | 11.29% | -19.22% | -47.14% | 15.00% | 99.28% | 106.85% |
| 2022 | -36.28% | -37.89% | 16.99% | -22.93% | -10.94% | 9.27% | -3.33% | -2.82% | 18.97% | 20.31% | -32.39% | -11.37% | -72.02% |
| 2021 | 32.41% | 26.04% | -7.44% | 14.29% | 13.67% | -4.12% | -25.09% | -5.26% | -14.65% | -13.02% | -19.73% | -19.47% | -34.47% |
Benchmark Metrics
Marker Therapeutics Inc has an annualized alpha of -7.09%, beta of 1.07, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since March 26, 2014.
- This stock participated in 173.01% of S&P 500 Index downside but only -53.18% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.09%
- Beta
- 1.07
- R²
- 0.03
- Upside Capture
- -53.18%
- Downside Capture
- 173.01%
Return for Risk
Risk / Return Rank
MRKR ranks 44 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Marker Therapeutics Inc (MRKR) and compare them to a chosen benchmark (S&P 500 Index).
| MRKR | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.06 | 0.90 | -0.84 |
Sortino ratioReturn per unit of downside risk | 0.85 | 1.39 | -0.54 |
Omega ratioGain probability vs. loss probability | 1.09 | 1.21 | -0.12 |
Calmar ratioReturn relative to maximum drawdown | 0.04 | 1.40 | -1.36 |
Martin ratioReturn relative to average drawdown | 0.07 | 6.61 | -6.53 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore MRKR risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Marker Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Marker Therapeutics Inc was 99.88%, occurring on Mar 31, 2023. The portfolio has not yet recovered.
The current Marker Therapeutics Inc drawdown is 99.78%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.88% | Mar 26, 2014 | 2271 | Mar 31, 2023 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Marker Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Marker Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MRKR relative to other companies in the Biotechnology industry. Currently, MRKR has a P/S ratio of 4.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |